Fulcrum Therapeutics’ (FULC) Neutral Rating Reaffirmed at HC Wainwright

Fulcrum Therapeutics (NASDAQ:FULC)‘s stock had its “neutral” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Tuesday, Marketbeat Ratings reports. They currently have a $3.00 price target on the stock. HC Wainwright’s price objective would indicate a potential downside of 53.27% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler cut shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating and set a $3.00 target price for the company. in a research note on Tuesday. Leerink Partners reaffirmed an “outperform” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Truist Financial set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $12.89.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $6.42 on Tuesday. The firm has a fifty day moving average price of $7.23 and a 200-day moving average price of $9.22. The stock has a market cap of $427.78 million, a PE ratio of -5.58 and a beta of 3.02. Fulcrum Therapeutics has a 1 year low of $5.88 and a 1 year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. On average, research analysts expect that Fulcrum Therapeutics will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FULC. Deutsche Bank AG lifted its holdings in shares of Fulcrum Therapeutics by 0.6% in the 4th quarter. Deutsche Bank AG now owns 287,096 shares of the company’s stock worth $3,247,000 after acquiring an additional 1,767 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 14.5% in the 4th quarter. Intech Investment Management LLC now owns 19,747 shares of the company’s stock worth $223,000 after acquiring an additional 2,503 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth about $30,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Fulcrum Therapeutics by 25.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company’s stock worth $124,000 after acquiring an additional 3,219 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth about $39,000. 89.83% of the stock is owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.